Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules01:18

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

396
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
396
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

405
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
405
Factors Influencing Drug Absorption: Pharmaceutical Parameters01:28

Factors Influencing Drug Absorption: Pharmaceutical Parameters

709
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
709
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

211
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
211
Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

279
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
279
Biopharmaceutics and Pharmacokinetics: Overview01:28

Biopharmaceutics and Pharmacokinetics: Overview

4.9K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of the Pediatric Type 2 Diabetes Impact Measure (P-TIM).

Journal of patient-reported outcomes·2026
Same author

Correction: Mixed-Methods to Define Meaningful Change using Exit Interview and Clinical Trial Data in Patients with Tenosynovial Giant Cell Tumor (TGCT).

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation·2026
Same author

Types and frequencies of adverse events across clinical trials for patients with amyotrophic lateral sclerosis: an analysis of the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
Same author

Development and Content Validity Evaluation of the Condition-Agnostic Treatment Goal Evaluation Scale (TGES) for Use in Chronic Conditions.

Patient related outcome measures·2026
Same author

Development of the Patient Satisfaction with Medication for Diabetes (PSMD) questionnaire.

Journal of patient-reported outcomes·2026
Same author

Psychometric Validation of the Simplicity of Diabetes Treatment Questionnaire (Sim-Q) for Type 2 Diabetes.

Advances in therapy·2026
Same journal

Determinants of Family Members' Willingness to Donate Organs in Intensive Care Units: A Cross-Sectional Study.

Patient preference and adherence·2026
Same journal

Symptom Clusters and Quality of Life in Cervical Cancer Patients During the Perioperative Period: A Longitudinal Study.

Patient preference and adherence·2026
Same journal

Development and Validation of the Behavioral Determinants of Deprescribing Questionnaire (BDDQ).

Patient preference and adherence·2026
Same journal

Facilitating and Hindering Factors in Discharge Preparation During the Hospital-to-Home Transition Period for Newly Diagnosed Tuberculosis Patients: A Qualitative Study.

Patient preference and adherence·2026
Same journal

Exploring Information Needs and Perspectives on a Patient Decision Aid for Biologic Therapy: A Qualitative Interview Study Among Individuals with Rheumatoid Arthritis.

Patient preference and adherence·2026
Same journal

The Need to Feel Safe: Older Adults' and Family Caregivers' Perspectives on Safe and Person-Centered Medication Management in Home Nursing Care.

Patient preference and adherence·2026
See all related articles

Related Experiment Video

Updated: Mar 16, 2026

Author Spotlight: Process Development for the Spray-Drying of Probiotic Bacteria and Evaluation of the Product Quality
05:45

Author Spotlight: Process Development for the Spray-Drying of Probiotic Bacteria and Evaluation of the Product Quality

Published on: April 7, 2023

4.5K

Preference for pharmaceutical formulation and treatment process attributes.

Katie D Stewart1, Joseph A Johnston2, Louis S Matza1

  • 1Outcomes Research, Evidera, Bethesda, MD, USA.

Patient Preference and Adherence
|August 17, 2016
PubMed
Summary
This summary is machine-generated.

Patients prefer simpler pharmaceutical treatments with less frequent dosing and less invasive administration. These patient preferences for treatment process attributes significantly impact their choices and willingness to pay, even when safety and efficacy are key concerns.

Keywords:
conjointcontingent valuationpharmaceutical formulationpreferencetreatment processutility

More Related Videos

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

4.6K
Automation of a Positron-emission Tomography PET Radiotracer Synthesis Protocol for Clinical Production
10:20

Automation of a Positron-emission Tomography PET Radiotracer Synthesis Protocol for Clinical Production

Published on: October 26, 2018

12.0K

Related Experiment Videos

Last Updated: Mar 16, 2026

Author Spotlight: Process Development for the Spray-Drying of Probiotic Bacteria and Evaluation of the Product Quality
05:45

Author Spotlight: Process Development for the Spray-Drying of Probiotic Bacteria and Evaluation of the Product Quality

Published on: April 7, 2023

4.5K
Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

4.6K
Automation of a Positron-emission Tomography PET Radiotracer Synthesis Protocol for Clinical Production
10:20

Automation of a Positron-emission Tomography PET Radiotracer Synthesis Protocol for Clinical Production

Published on: October 26, 2018

12.0K

Area of Science:

  • Pharmacoeconomics
  • Patient-reported outcomes
  • Drug development

Background:

  • Pharmaceutical formulation and treatment process attributes significantly influence patient quality of life, treatment adherence, and overall disease outcomes.
  • Understanding patient preferences for these attributes is crucial for optimizing therapeutic strategies.

Purpose of the Study:

  • To systematically review and analyze studies investigating patient preferences for pharmaceutical treatment process attributes.
  • Focus on key therapeutic areas including diabetes, oncology, osteoporosis, and autoimmune disorders.

Main Methods:

  • Conducted a comprehensive literature search of major databases (Medline, EMBASE, Cochrane Library, etc.) from January 1993 to October 2013.
  • Included studies that employed formal quantitative preference assessment methods like utility valuation, conjoint analysis, or contingent valuation.
  • Analyzed 42 studies meeting inclusion criteria across the specified disease areas.

Main Results:

  • Across diverse conditions, patients consistently preferred treatments characterized by shorter duration, less frequent administration, greater flexibility, and less invasive routes.
  • While efficacy and safety were often paramount, treatment process attributes demonstrated a quantifiable impact on patient preference and willingness to pay.
  • The relative importance of treatment process attributes varied based on disease characteristics and individual patient factors, such as prior injection experience.

Conclusions:

  • Patient preferences for pharmaceutical treatment process attributes are significant and quantifiable, influencing treatment choices beyond just efficacy and safety.
  • These insights into patient preferences can guide pharmaceutical companies in drug development to create more patient-centric treatments.
  • Aligning drug development with patient preferences for treatment process attributes can lead to improved adherence and better health outcomes.